Tempest Therapeutics, Inc. (OVAS) [Rocket]

In millions, except per share items	Jun-30-23	Mar-31-23	Dec-31-22	Sep-30-22	Jun-30-22	Mar-31-22	Dec-31-21	Sep-30-21
	10-Q	10-Q	10-K	10-Q	10-Q	10-Q	10-K	10-Q
Operating expenses:
Research and development	20.9	22.1	22.5	21.4	20.1	18.7	17.2	16.1
General and administrative	11.9	12.0	12.1	11.6	11.9	11.3	9.8	10.7
Loss from operations	-32.8	-34.1	-34.6	-33.0	-32.0	-30.0	-27.0	-12.5

Other income (expense), net:
Interest expense	-1.5	-1.6	-1.6	-1.5	-1.6	-1.4	-1.3	-0.9
Interest income and other income (expense), net	0.0	-0.2			0.0	0.0	0.0
Total other income (expense), net	-0.6	-1.1	-1.1	-1.3	-1.5	-1.4	-1.3	-0.9
Net loss	-33.3	-34.9	-35.7	-34.4	-33.5	-31.4	-28.3	-27.9

Net loss per share of common stock and pre-funded warrants, basic	($2.38)	($2.63)	($3.26)	($2.61)	($3.16)	($10.00)	($19.37)	($19.78)
Net loss per share of common stock and pre-funded warrants, diluted	($2.38)	($2.63)	($3.26)	($2.61)	($3.16)	($10.00)	($19.37)	($19.78)

Weighted-average shares of common stock and pre-funded warrants outstanding, basic	13.3	12.6	11.0	9.0	7.3	4.7	3.0	6.8
Weighted-average shares of common stock and pre-funded warrants outstanding, diluted	13.3	12.6	11.0	9.0	7.3	4.7	3.0	2.0